NRBO Company Profile and Key Details

Q: Who are the executives of NRBO?

Dr. Ben Gil Price M.D.Chief Executive Officer & PresMr. Frank KondradVice President of Corporation & Bus. Devel.Dr. Matthew Bardin BCPS, Pharm.D.Senior Vice President of OperationsMr. Joseph HookerInterim Chief Executive Officer & Pres

NASDAQ : NRBO

NeuroBo Pharmaceuticals

$2.36

N/A-

Open: 4:00 PM

Not Actively Trading

66.16

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

NeuroBo Pharmaceuticals, Inc. (NRBO) stock remained unchanged at -, trading at $2.36 on NASDAQ, unchanged from the previous close of -. The stock opened at -, fluctuating between $2.36 and $2.36 in the recent session.

Stock Snapshot

N/A

Prev. Close

20.33M

Market Cap

2.36

Day Low

-0.5501165501165501

P/E Ratio

-4.29

EPS (TTM)

-2.14

Cash Flow per Share

N/A

Open

8.62M

Number of Shares

2.36

Day High

24.39%

Free Float in %

3.28

Book Value

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 23, 2024	1.66	1.67	1.51	1.63	96.8K
Dec 20, 2024	1.65	1.78	1.60	1.60	150.58K
Dec 19, 2024	1.72	1.83	1.69	1.76	129.62K
Dec 18, 2024	2.00	2.10	1.55	1.85	4.88M
Dec 17, 2024	2.35	2.38	2.17	2.25	22.65K
Dec 16, 2024	2.30	2.50	2.16	2.21	39.21K
Dec 13, 2024	2.30	2.38	2.18	2.19	35.82K
Dec 12, 2024	2.40	2.48	2.30	2.31	24.54K
Dec 11, 2024	2.27	2.50	2.24	2.37	11.86K
Dec 10, 2024	2.41	2.41	2.18	2.26	40.44K
Dec 09, 2024	2.24	2.35	2.24	2.32	16.25K
Dec 06, 2024	2.39	2.45	2.04	2.31	22.49K
Dec 05, 2024	2.37	2.54	2.28	2.30	30.29K
Dec 04, 2024	2.45	2.47	2.28	2.45	27.19K
Dec 03, 2024	2.58	2.63	2.35	2.57	18.33K
Dec 02, 2024	2.33	2.65	2.33	2.60	40.53K
Nov 29, 2024	2.31	2.65	2.31	2.55	12.78K
Nov 27, 2024	2.35	2.44	2.32	2.36	13.07K
Nov 26, 2024	2.37	2.44	2.30	2.35	19.12K
Nov 25, 2024	2.50	2.54	2.38	2.42	26.6K

Contact Details

Boston, MA 02116

United States

https://www.neurobopharma.com 857 702 9600

About Company

NeuroBo Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm committed to advancing treatments for a spectrum of challenging conditions, encompassing neurodegenerative disorders, infectious diseases, and cardiometabolic ailments. The company's diverse pipeline includes several investigational therapies: ANA001, an orally administered formulation of niclosamide, is currently progressing through Phase 2/3 clinical trials to treat individuals with moderate coronavirus disease (COVID-19). NB-01 is being developed to alleviate the discomfort associated with painful diabetic neuropathy. NB-02 targets the management of cognitive decline symptoms and seeks to alter the course of neurodegenerative conditions specifically linked to the malfunction of tau protein. Gemcabene is also part of their portfolio, under investigation for its potential in acute COVID-19 indications. NeuroBo Pharmaceuticals, Inc. maintains its corporate headquarters in Boston, Massachusetts.

Stock Peers

ARGX

28.55+3.37%

argenx SE$874.74 REGN

3.04+0.45%

Regeneron Pharmaceuticals, Inc.$675.19 MDGL

11.1+2.07%

Madrigal Pharmaceuticals, Inc.$546.79 UTHR

6.49+1.23%

United Therapeutics Corporation$535.83 VRTX

1.5+0.31%

Vertex Pharmaceuticals Incorporated$482.00 KRYS

-0.16-0.05%

Krystal Biotech, Inc.$339.06 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

8.11+2.61%

BeOne Medicines AG$318.69 PRAX

13.44+4.41%

Praxis Precision Medicines, Inc.$317.87 LGND

11.48+3.90%

Ligand Pharmaceuticals Incorporated$305.47

Company Overview

The stock is currently trading near its 52-week high $2.36 and $2.36. With a market capitalization of about $20.33 million, NeuroBo Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.28). Headquartered in Boston, MA, NeuroBo Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Hyung-Heon Kim, the company employs approximately 8 people and listed since August 05, 2016. NeuroBo Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm committed to advancing treatments for a spectrum of challenging conditions, encompassing neurodegenerative disorders, infectious diseases, and cardiometabolic ailments.

Technical Performance

NRBO has shown mixed momentum, gaining 8.51% over the past week and -30.89% over the past quarter, though year-to-date performance is down -31.02%. Short-term trend indicators are bullishly aligned (SMA20 -5.49%, SMA50 -13.69%, SMA200 -37.98%). The stock’s 14-day RSI is 40.85 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -65.04% below its high and over 13.46% above its low.

Valuation Metrics

NeuroBo Pharmaceuticals, Inc. trades at a P/E ratio of -0.3, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1264.03 reflecting a rich premium to book value. The P/FCF stands at -1.34, also above market averages. Compared to sector medians, NeuroBo Pharmaceuticals, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

NeuroBo Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.38. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

NeuroBo Pharmaceuticals, Inc. generated EPS of -$4.29 over the past year. Five-year average earnings growth is 69.1%. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.89. Next year's EPS is expected at -$64.29. NeuroBo Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended March 27, 2025, missed forecasts by -92.51%. The prior quarter beat by -99.92%. Over the last six quarters, Apple has recorded several small beats. These include 192.31% in March 28, 2024.

Shareholding & Insider Activity

NeuroBo Pharmaceuticals, Inc. has 8.62 million shares outstanding. The public float is 2.10 million shares, elevated short interest at 1.06% of float. This equals 34.27 thousand shares. The short ratio is 0.87 days. Institutional investors hold 36.57% of the float. Insiders own 65.23%. DONG-A ST CO., LTD holds 2.54 million shares, Bisgaier Charles PhD has 1.24 million shares and Gullans Steven R. Ph.D. has 930.25 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, NeuroBo Pharmaceuticals generated $7.00K in revenue, or $0.00 per share. Gross margin was 0.00%, operating margin -226942.86%, and net profit margin -178142.86%. Returns are negative, with ROA at -54.74% and ROE at -74.74%.
On valuation metrics, NeuroBo Pharmaceuticals trades at a P/E of -0.30, P/S of 0.00 and P/B of 1264.03. The current ratio is 2.73 and quick ratio is 2.73. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -78.06.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, NeuroBo Pharmaceuticals posted revenue of $7.00K, down slightly from $0.00 in the prior quarter. Gross profit was $0.00 (margin 0.00%). Operating income was - $15.89M (margin -226942.9%). Net income was- $12.47M (EPS - $2.46).
The company ended the quarter with $22.44M in cash and short-term investments, a total debt of $203.00K, and net debt of - $22.23M. Total assets were $22.78M, with equity of $16.68M. Financials further reflected weakness, with operating cash flow of - $10.80M, free cash flow of - $10.85M, and capital expenditures of - $50.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that NeuroBo Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.61%, with price expected at $1.62 by January 06, 2025, within a range of $1.42 to $1.82 3-Month Outlook: Projected rise of 623.93%, reaching $11.80 by February 25, 2025, with a range of $11.32 to $12.26. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by November 28, 2025, within a range of $0.00 to $21.92.

Key Takeaways

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) shares are down -31.02% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NeuroBo Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.3. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.00, suggesting 636.2% upside. Our AI forecast model points to short-term weakness (-0.61% over two weeks), a medium-term rise (623.93% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current NeuroBo Pharmaceuticals, Inc. (NRBO) stock price?

NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) stock price is $2.36 in the last trading session. During the trading session, NRBO stock reached the peak price of $2.36 while $2.36 was the lowest point it dropped to. The percentage change in NRBO stock occurred in the recent session was N/A while the dollar amount for the price change in NRBO stock was -.

NRBO's industry and sector of operation?

The NASDAQ listed NRBO is part of Biotechnology industry that operates in the broader Healthcare sector. NeuroBo Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NRBO?

Dr. Ben Gil Price M.D.
Chief Executive Officer & Pres
Mr. Frank Kondrad
Vice President of Corporation & Bus. Devel.
Dr. Matthew Bardin BCPS, Pharm.D.
Senior Vice President of Operations
Mr. Joseph Hooker
Interim Chief Executive Officer & Pres

How NRBO did perform over past 52-week?

NRBO's closing price is 0% higher than its 52-week low of $2.36 where as its distance from 52-week high of $2.36 is 0%.

How many employees does NRBO have?

Number of NRBO employees currently stands at 8.

Link for NRBO official website?

Official Website of NRBO is: https://www.neurobopharma.com

How do I contact NRBO?

NRBO could be contacted at phone 857 702 9600 and can also be accessed through its website. NRBO operates from 200 Berkeley Street, Boston, MA 02116, United States.

How many shares of NRBO are traded daily?

NRBO stock volume for the day was 0 shares. The average number of NRBO shares traded daily for last 3 months was 0.

What is the market cap of NRBO currently?

The market value of NRBO currently stands at $20.33M with its latest stock price at $2.36 and 8.62M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	8
Beta	-0.28
Sales or Revenue	$7.00K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NRBO Company Profile and Key Details

NeuroBo Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook